Unjoni Ewropea - Malti - EMA (European Medicines Agency)

amgen europe b.v. - pegfilgrastim - newtropenja - immunostimulanti, - tnaqqis fit-tul tal-neutropenia u l-inċidenza tal-marda bid-deni neutropenia fil-pazjenti adulti ttrattati ċitotossiċi chemotherapy għall-malignancy (bl-eċċezzjoni ta ' kronika myeloid lewċemja u myelodysplastic sindromi).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, tromboċitopenika, idjopatika - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 u 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 u 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mundipharma corporation (ireland) limited - pegfilgrastim - newtropenja - immunostimulanti, - biex inaqqas id-dewmien ta 'newtropenja u l-inċidenza ta' newtropenja bid-deni minħabba l-kimoterapija.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - avatrombopag maleate - tromboċitopenja - sustanzi kontra l-emorraġija - doptelet huwa indikat għall-kura ta ' tromboċitopenja qawwija f'pazjenti adulti b'mard kroniku tal-fwied li huma skedati li jgħaddu minn proċedura invażiva. doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. kortikosterojdi, immunoglobulini).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mundipharma corporation (ireland) limited - pegfilgrastim - newtropenja - immunostimulanti, - tnaqqis fit-tul tal-neutropenia u l-inċidenza tal-marda bid-deni neutropenia fil-pazjenti adulti ttrattati ċitotossiċi chemotherapy għall-malignancy (bl-eċċezzjoni ta ' kronika myeloid lewċemja u myelodysplastic sindromi).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ucb pharma s.a. - romosozumab - l-osteoporożi - drogi għat-trattament ta 'mard tal-għadam - evenity huwa indikat fit-trattament ta 'l-osteoporożi fin-nisa wara l-menopawsa f'riskju għoli ta' ksur.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - aġenti antineoplastiċi - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - eftrenonacog alfa - hemofilja b - il-vitamina k u oħra hemostatics, fatturi ta ' koagulazzjoni tad-demm - trattament u profilassi ta 'fsada f'pazjenti b'emofilja b (defiċjenza konġenitali tal-fattur ix).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

recordati ireland ltd. - lidocaine, prilocaine - disfunzjoni sesswali, fiżjoloġika - anestetiċi - trattament tal-eġakulazzjoni primarja prematura fl-irġiel adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi pasteur - hepatitis b surface antigen, diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens pertussis toxoid filamentous haemagglutinin, poliovirus (inactivated) type 1 (mahoney) type 2 (mef-1) type 3 (saukett), haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines, bacterial and viral vaccines, combined - hexacima (dtap-ipv-hb-hib) huwa indikat għat-tilqim primarja u booster tat-trabi u toddlers minn sitt ġimgħat ta ' età kontra diphtheria, tetanus, pertussis, epatite b, poliomyelitis u invażivi mard ikkawżat minn influwenza Ħemofillika tip b (hib). l-użu ta ' dan il-vaċċin għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.